High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: Does NT-proBNP help to explain this association?

European Journal of Preventive Cardiology

Volumn 18, Issue 1, 2011, Pages 65-71

  Wannamethee, Sasiwarang Goya ^a   Welsh, Paul ^c   Whincup, Peter h ^b   Sawar, Nadeem ^d   Thomas, Mary c ^a   Gudnarsson, Vilmundur ^e   Sattar, Naveed ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Adiponectin; cardiovascular disease; epidemiology; N terminal fragment pro brain natriuretic peptide

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; HEART DISEASE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE MASS; PRIORITY JOURNAL; RISK FACTOR;

ADIPONECTIN; AGE FACTORS; AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; UP-REGULATION;

EID: 79959206909     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32833b09d9     Document Type: Article

References (33)

1. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action. Regulation and association to insulin sensitivity. Obes Rev 2005; 6: 13–21.
2. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–1737.
3. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006; 48: 1369–1377.
4. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007; 92: 571–576.
5. Kanaya AM, Wassel Fyr C, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, et al. Health ABC Study. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 2006; 91: 5044–5050.
6. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114: 623–629.
7. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005; 90: 5677–5683.
8. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: e15–e16.
9. Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur Heart J 2006; 27: 2266–2268.
10. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adipoenctin and coronary heart disease and mortality: the Rancho Bernardo Study. Am J Epidemiol 2007; 165: 164–174.
11. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 1510–1517.
12. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489–1496.
13. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008; 93: 3357–3364.
14. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008; 93: 3299–3301.
15. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177–2187.
16. Ang DS, Welsh P, Watt P, Nelson SM, Struthers A, Sattar N. Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clin Sci (Lond) 2009; 117: 41–48.
17. Ohara T, Kim J, Asakura M, Asanuma H, Nakatani S, Hashimura K, et al. Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens Res 2008; 31: 825–831.
18. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981; 283: 179–186.
19. Morris RW, Walker M, Lennon LT, Shaper AG, Whincup PH. Hard drinking water does not protect against cardiovascular disease: new evidence from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil 2008; 15: 185–189.
20. Macfarlane PW, Devine B, Latif S, McLaughlin S, Shoat DB, Watts MP. Methodology of ECG interpretation in the Glasgow program. Methods Inf Med. 1990; 29: 354–361.
21. Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 1785–1790.
22. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Rumley A, Brown K, et al. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes 2007; 31: 1089–1098.
23. Ramsay SE, Morris RW, Wincup PH, Papacosta O, Rumley A, Lennon L, et al. Socioeconomic inequalities in coronary heart disease risk in older age: contribution of established and novel coronary risk factors. J Thromb Haemost 2009; 7: 1779–1786.
24. Emberson JR, Whincup PH, Morris RW, Walker M, Lowe GDO, Rumley A. Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil 2004; 11: 125–134.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
26. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Decreased muscle mass and increased central adiposity are independently related to mortality in older men. Am J Clin Nutr 2007; 86: 1339–1346.
27. Levy AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470.
28. Walker M, Shaper AG, Lennon L, Whincup PH. Twenty year follow-up of a cohort study based in general practices in 24 British towns. J Publ Health Med 2000; 22: 479–485.
29. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods, 2nd ed. Geneva. Switzerland: World Health Organisation, 1982.
30. Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent ‘pancardiac’ target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 2007; 28: 1678–1682.
31. Sengenes C, Moro C, Galitzky J, Berlan M, Lafontan M. Natriuretic peptides: a new lipolytic pathway in human fat cells. (Med Sci Paris) 2005; 21: 29–33.
32. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009; 53: 2070–2077.
33. The World Health Organization MONICA Project. (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41: 105–114.